LUNG AND RESPIRATORY SYSTEM DISEASES (E.G., ASTHMA, EMPHYSEMA)

Аннотация

Lung and respiratory system diseases, such as asthma and emphysema, represent significant global health challenges due to their prevalence, impact on quality of life, and economic burden. Asthma, a chronic inflammatory disorder of the airways, and emphysema, a progressive disease characterized by the destruction of the alveolar walls, are two common respiratory conditions that affect millions of people worldwide. This paper explores the pathophysiology, mechanisms, and clinical implications of asthma and emphysema, discussing their etiology, diagnosis, and treatment options. Through a detailed review of the existing literature, this paper aims to provide a comprehensive understanding of these diseases and the latest advancements in their management. Keywords: Asthma, Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Airway inflammation, Alveolar destruction, Respiratory diseases, Bronchodilators, Inhaled corticosteroids. Introduction: Lung and respiratory system diseases, such as asthma and emphysema, are among the leading causes of morbidity and mortality globally. These conditions have a profound impact on the quality of life of affected individuals and place a significant burden on healthcare systems worldwide. Asthma and emphysema, though distinct in their pathophysiology, both involve chronic respiratory symptoms that include shortness of breath, wheezing, cough, and reduced exercise capacity. Despite their differences, both conditions share the characteristic of obstructed airflow, which can lead to respiratory failure in severe cases. Asthma is a chronic inflammatory disease of the airways that causes intermittent episodes of wheezing, breathlessness, and cough, often triggered byenvironmental factors such as allergens, respiratory infections, orair pollution. The hallmark ofasthma is airway hyperresponsiveness, in which the airways become excessively reactive to stimuli that would not affect normal airways. The inflammatory process involves various immune cells, including T-helper 2 (Th2) cells, eosinophils, and mast cells, which contribute to airway constriction and mucus production. Asthma can affect individuals of any age, but it often starts in childhood and may persist into adulthood. It is a disease that can vary in severity, from mild intermittent symptoms to severe, persistent asthma that significantly impairs daily functioning. In contrast, emphysema is a progressive and irreversible lung disease that is part of the broader spectrum of chronic obstructive pulmonary disease (COPD). Emphysema primarily results from long-term exposure to harmful particles, most notably cigarette smoke. This exposure leads to inflammation and the destruction of the alveolar walls, impairing the lungs' ability to exchange oxygen and carbon dioxideefficiently. The disease is characterized by the loss of elastic recoil in the lung tissue, causing the airways to collapse during exhalation and leading to airflow limitation. The progressive nature of emphysema means that symptoms worsen over time, and patients often experience chronic cough, excessive sputum production, and worsening dyspnea (shortness of breath). Unlike asthma, which is primarily reversible with appropriate treatment, emphysema is irreversible, and its progression is largely dependent on ongoing exposure to harmful substances. www.wordlyknowledge.uz ILMIYMETODIK JURNAL JOURNAL OFIQRO –ЖУРНАЛ ИҚРО –IQRO JURNALI –volume 14,issue02,2025 ISSN:2181-4341, IMPACT FACTOR( RESEARCH BIB )–7,245,SJIF–5,431 While the primary risk factor for emphysema is smoking, it is also associated with genetic factors, such as a deficiency in alpha-1 antitrypsin, an enzyme that helps protect the lungs from protease activity. This deficiency increases susceptibility to emphysema even in non-smokers. Asthma, on the other hand, has a stronger link to genetic predisposition and environmental exposures, with allergic reactions often playing a major role in disease exacerbation. Both conditions have significant implications for patients’ health, as they can lead to chronic symptoms, frequent hospitalizations,and adecreased quality oflife. Literature review Lung diseases, particularly asthma and emphysema, are both highly prevalent and carry a significant burden on individuals and healthcare systems worldwide. Asthma is a chronic inflammatory disease of the airways characterized by reversible airflow obstruction, while emphysema is part of the spectrum of Chronic Obstructive Pulmonary Disease (COPD) and is characterized by irreversible destruction of alveolar walls and the loss of lung elasticity. Despite differences in their pathophysiology, both conditions lead to significant respiratory symptoms, such as dyspnea, coughing, and wheezing, that impair the quality of life and increase healthcare utilization. Asthma: Pathophysiology and Mechanisms: Asthma is an inflammatory disorder that affects the airways, leading to chronic inflammation, airway hyperresponsiveness, and bron